model. A piecewise linear change-point Poisson regression model was used to compare mortality rates in Tyrol and the rest of Austria. Standardized mortality ratios were calculated with reference to the mortality rates in [1986][1987][1988][1989][1990].
INTRODUCTION
Since PSA testing for prostate cancer became available, both incidence and mortality rates have changed profoundly; between 1989 and metastatic disease at diagnosis and a corresponding 32.5% decrease in the ageadjusted mortality rate from 1993 to 2003 [3, 4] .
Randomized, controlled trials evaluating the efficacy of PSA and DRE screening in reducing prostate cancer mortality are underway [5] [6] [7] , but the results will not be available for several years. Furthermore, the randomized design of these trials may be compromised if nonadherence to the assigned intervention group is extensive, i.e. widespread contamination of the control group from members seeking PSA testing [8] . The consequences on the statistical power of these trials could be considerable [9] .
It is essential to separate the question of efficacy of screening from the effectiveness of a well-controlled screening and treatment programme. The present study reports the incidence and mortality rates of prostate cancer in the Federal State of Tyrol, Austria, where PSA testing started in 1988 and has been made freely available to the population of men aged 45-75 years since 1993. Incidence, stage migration and mortality rates of the Tyrol study are reported. The issues of diagnoses, how PSA can be used intelligently, the value of anatomical radical prostatectomy (RP) and the problem of over-diagnosis are discussed concerning the qualitative effects of prostate cancer screening. PSA testing was not available free of charge in the rest of Austria, although it was used, probably developing in a similar manner to use in many Western countries. Comparing mortality rates between Tyrol and the rest of Austria allows evaluation of the outcome of this natural experiment.
SUBJECTS AND METHODS

STUDY DESIGN
Since 1988, early prostate cancer detection has been promoted by the Department of Urology of the University of Innsbruck, Austria, using both PSA and DRE in the diagnostic evaluation of asymptomatic healthy men. Since 1993, this early prostate cancer detection programme has been carried out in the Federal State of Tyrol (one of the nine Federal States of the Republic of Austria) with prospective data collection and documentation, as well as with the development of an associated biorepository.
Details of all individual PSA test results and biopsies, with a unique identifier for the individual man, are recorded so that the cancer registry in Tyrol is able to ascertain which men have had at least one PSA test and hence calculate the numbers of men who have not been tested.
Tyrol is an alpine region in western Austria with, at the 1991 census, 631 410 inhabitants (324 161 women and 307 249 men) in an area of 12 647 km 2 . At the same census, the total population of Austria was 7.81 million with 4.05 million women and 3.76 million men. Tyrol is dominated by the mountains of the Central Alps, and the distances to Innsbruck, the capital, where the central health care unit is located, are not great (infrequently > 100 km). This geographical situation, as well as the willingness of the general population to participate in preventive medical programmes, is well suited for a state-wide mass screening programme, with PSA as the first-line screening test for the early detection of prostate cancer.
PSA testing was made freely available by the Social Insurance Company of the Federal State of Tyrol and the University Hospital of Innsbruck to all men aged 45-75 years who were inhabitants of Tyrol. Of the 307 249 male inhabitants in 1993, 86 067 were aged 45-75 years. All men in this age range were advised and encouraged to undergo PSA testing; the information of advantages and disadvantages was distributed to all Tyrolean men by press, radio, and television. All these releases were approved by the Review Board of the Prostate Centre at the Department of Urology, University of Innsbruck.
The Screening Demonstration Project was performed in collaboration with GPs, medical examiners, urologists, medical laboratories, and the Tyrol Blood Bank of the Red Cross. The study protocol was approved by the Review Board of the Prostate Centre at the Department of Urology, University of Innsbruck. Informed consent was obtained from all volunteers participating in the programme. All co-workers were fully informed of the guidelines for withdrawal, storage, and shipping of the blood samples. The PSA level was assessed immediately on arrival of the blood or serum sample. All volunteers and/or referring physicians were informed about the results in writing. In the case of elevated PSA levels, the volunteers were invited to undergo additional urological evaluations at no cost, and the men with normal PSA levels were invited to have a repeated PSA test 6 or 12 months later. At the time of drawing blood for PSA measurement, no DRE was performed.
PSA testing was provided free of charge to men aged 45-75 year and to younger men (40 years) with a family history of prostate cancer. In all laboratories, the PSA concentration was assessed using the Abbott IMx assay (Abbott Park, IL, USA).
DIAGNOSIS
From September 1993 to September 1995, age-referenced PSA levels [10] (40-49 years: 0-2.5 ng/mL, 50-59 years: 0-3.5 ng/mL, 60-69 years: 0-4.5 ng/mL, 70-79 years: 0-6.5 ng/mL) in combination with percentage-free PSA levels of < 22%, were used as the criteria for recommending biopsy. Since October 1995, lower PSA levels [11] (45(40) − 49 years: 0-1.25 ng/mL, 50-59 years: 0-1.75 ng/mL, 60-69 years: 0-2.25 ng/mL, 70-79 years: 0-3.25 ng/mL), together with percentage-free PSA levels of < 18% were used. In March 1996, an artificial neural network was constructed, using total PSA, free PSA, age, DRE and TRUS variables. Using this neural network the probability of having cancer could be estimated. In 2005, the concept of PSA-velocity [12] was incorporated in the diagnostic evaluation to further enhance the specificity of the programme (Fig. 1 ).
All men who met the above-mentioned biopsy criteria, were invited to undergo additional urological evaluation, including DRE and TRUS-guided biopsies of the prostate. Urologists performed the DRE and TRUS During the 5-year study period, it was assumed that PSA screening could affect death rates in the age group beyond screening age range (75-79 years); therefore, truncated mortality rates were considered to age 79 years. Incidence and mortality rates for the age range of 40-79 years were calculated, using the World Standard Population as reference [15] .
The principal hypotheses to be tested can be expressed as follows: (i) do prostate cancer mortality rates in Tyrol decrease from 1993; (ii) do trends in prostate cancer mortality rates in Tyrol differ from those in the rest of Austria from 1993 onwards. Trends in the mortality rates, for age group, i , and year, y , in Tyrol and the rest of Austria were compared within a Poisson regression model:
This is a 'change-point' model in which the term I ( y ≥ 1993) is an indicator that permits there to be a different slope from 1993 A possible criticism of this analysis is that it assumes a change-point model with linear trends for year. As there is a much longer follow-up relative to our previous analysis, we relaxed this assumption using a generalized additive model [17] where the linear trends are replaced by smooth splines:
In this model, s 1 ( ) represents the trend in the rates in the rest of Austria, while s 2 ( ) represents the trend in Tyrol. All statistical analysis was carried out using Splus 7.0 [18].
As previously reported [19] , the estimated benefit of the mass-screening programme was calculated by comparing the observed and expected numbers of prostate cancer deaths in Tyrol and by comparing the prostate cancer mortality trends in Tyrol with the rest of Austria. The expected numbers of deaths for each year in Tyrol were calculated using the age-specific averages of the rates from 1986 to 1990 as the reference. This calculation was carried out for men aged 40-79 years and for men aged ≥ 80 years. . RP was associated with a low morbidity rate; the 30-day mortality was zero, and none of the patients had a ureteric injury. The rectal injury rate decreased from 0.6% before the year 2000 to 0.1% thereafter. Of the patients, 0.7% had postoperative bleeding requiring intervention. At 3 months after RP, 80.6% of men had recovered urinary continence (no pads), which increased to 95.1% by 1 year, and erectile potency was preserved in 78.9% of men aged < 65 years.
The incidence rate of prostate cancer in men aged 40-79 years in Tyrol increased from 1988 until 1999/2000 and has remained essentially constant since. In the Tyrol, the incidence rate of organ-confined disease (clinical stage T1-T2, M0) increased from 1988 until 2000, when the rate leveled off. In the rest of Austria, the incidence rate for T1-T2, M0 prostate cancer, which was lower than that in the Tyrol from 1990, has increased gradually and in 2003 was at the same level as Tyrol (Fig. 3) . The incidence of metastatic prostate cancer (M1) was lower in the Tyrol, especially since ≈ 1995/6, but there is now evidence that the rates are converging (Fig. 3) . Although, there were no statistically significant differences between Tyrol and the rest of Austria before 1993 the fitted value in Tyrol in 1993 is slightly higher than in the rest of Austria (Fig. 4) , and this may have some implications for the change in the slope.
To investigate the effect of this we constrain the line before 1993 to be exactly the same in Tyrol as in the rest of Austria. This is achieved by setting β 3 and β 4 both equal to zero in the model. Now the rate of increase in the log mortality rates is 0.007 ( SE 0.001) per year, which is very similar to that for the rest of Austria above as Tyrol is a small part of Austria. In the rest of Austria the rate of decrease from 1993 onwards is 0.033 ( SE 0.003) per year while in the Tyrol it is 0.065 ( SE 0.007) per year. The test statistic for the comparison of the slopes from 1993 onwards is chi-squared 21.08 ( P < 0.001).
The standardized mortality ratios in Table 2 show a reduction in prostate cancer deaths, among men aged 40-79 years, relative to those expected on the basis of the agespecific rates in the immediate pre-screening years (1986) (1987) (1988) (1989) (1990) SMR, standardized mortality ratio.
In 1996-2005, there were 567 expected (based on pre-testing rates from 1980 to 1990), but only 347 observed prostate cancer deaths (reduction 38.8%). As shown by the expected and observed deaths rates in men aged >80 years, there was a smaller, yet still substantial, decrease in the prostate cancer mortality rate (2002) (2003) (2004) (2005) , men aged >80 years: 187 expected deaths, 134 observed deaths, a reduction of 28.4%).
DISCUSSION
The present report is based on a demonstration project conducted in the population of Tyrol, Austria, where PSA testing has been offered to men free of charge since 1993. Even without a system of invitation and re-invitation, >80% of men aged 45-74 years underwent at least one PSA test for screening in the years 1993-2005 (Table 1) .
During the past decade, there has been a dramatic stage migration for newly diagnosed prostate cancer. Currently, 80% of men are diagnosed with prostate cancer while it is pathologically organ-confined, compared with only 20-30% in the 'pre-PSA era' [20] . In the Surveillance, Epidemiology and End Results programme, the rate of distant disease fell by 52% between 1990 and 1994 [21] .
A similar favourable stage migration is documented in the Tyrol Project and can almost certainly be attributed, at least in part, to the widespread acceptance of PSA-based prostate cancer screening. Several studies have clearly shown that cancers detected because of a PSA elevation are more likely to be organ-confined than those detected because of an abnormal DRE [20] [21] [22] [23] [24] [25] [26] .
The prostate cancer incidence data from Tyrol show that the age-standardized rate for metastatic cancer decreased from 5.2 to 2.1 per 100 000 and for advanced cancer (Union Contre le Cancer stage IV) from 7.9 to 3.7 per 100 000 from 1988-1992 to 1998-2002. This is consistent with a population-based, case-control study reporting that among asymptomatic men, the frequency of PSA-testing was significantly lower among men with metastatic prostate cancer [27] .
As PSA thresholds lower than the traditional 4 ng/mL for recommending a prostate biopsy were adopted, a highly significant increase in the proportion of patients with pathologically organ-confined disease has been observed: this rose from 23.7% in 1993 to 78.7% in 2005. Similar results were reported in a 12-year PSA-based screening study when the pathological features of prostate cancers detected were compared from three consecutive time intervals [28] .
Screening for prostate cancer, viewed as the first step in patient management would not lead to an improved outcome if the cancers detected were either clinically insignificant, already incurable or if the available treatment options were ineffective. For prostate cancer this has been shown not to be the case. The Scandinavian Prostate Cancer Group Study reported on outcomes of 347 men with early, nonscreendetected prostate cancer randomized to RP, compared to 348 men randomized to watchful waiting [29] . The risk of overall mortality, cancer-specific mortality, distant metastasis, and local progression were all significantly lower in the patients treated with RP after 8 years of follow-up. After 10 years, there also was a significant improvement in overall survival in patients treated with RP [29] .
It is probable that treatment with the intention to cure for early prostate cancer has contributed to the decreases in prostate cancer mortality observed in countries such as the USA, where treatment with RP and radiation therapy is widely practised.
Extrapolating these findings to a population of men who undergo screening, the removal of small tumours should improve survival by detecting the life-threatening tumours earlier.
In the Tyrol screening project, the treatment of patients with clinical stage T1-T2 lesions was RP in 89.3%, performed largely in a highvolume tertiary referral centre by experienced surgeons and was associated with low morbidity [30] (95.1% urinary continence (no pads) 1 year after RP; 78.9% preservation of erectile potency in men aged <65 years ). The probability of clinical cancer progression after RP in patients with low PSA levels (<4 ng/mL), a low positive surgical margin rate (4.2%), and a low biochemical recurrence rate (5.7%), is low. Therefore, in the long term, patients with early-stage prostate cancer that is detected through PSA screening, who are treated effectively, should be expected to have a lower prostate cancer mortality rate.
The controversy surrounding screening for prostate cancer with PSA revolves around three key issues. Does PSA identify clinically significant prostate cancer in most cases? Does aggressive intervention with surgery or radiation alter the outcome in men diagnosed with clinically significant disease? Does diagnosis and treatment seriously impinge of quality of life (QoL)?
The estimates of prostate cancer overdiagnosis (30-50%) have been exaggerated in the literature [31, 32] . This may be due in part by the fact that much of the data have been derived from older men, in whom overdiagnosis is a greater concern because of their limited life expectancy. In younger men, who are most likely to benefit from early diagnosis and treatment, the criteria for calling overdiagnosis are much less frequently met (≈15%) [32] . Nevertheless, a recent study showed that even men aged >65 years have a mortality benefit from treatment with RP or radiation therapy [33] . In the Tyrol study, in which the mean age of screened men was <65 years, the estimate of over-diagnosis according to the criteria of Epstein et al. [34] was 8.7% [35] .
Using the pathology criteria in the RP specimen for over-diagnosis of pathological stage T2a, Gleason <7, over-diagnosis in the Tyrol Project was 19.7% for PSA levels of 2-4 ng/mL and 17.6% for PSA levels of 2-10 ng/ mL [34] . In another screening study, using the Ohori criteria for unimportant disease [25] , <10% of men underwent treatment for overdiagnosed prostate cancer [36] .
Although reduction in prostate cancer mortality rates are important, it is also necessary to consider the effects of prostate cancer screening and treatment on patient QoL. Potential gains in survival could be more than offset by decrements in QoL that might result from diagnosis and treatment [37] . Ecological data suggest that 10-30% of the geographical variation in mortality rates might relate to variations in access to medical care [38] . A key feature of the present study setting is that patients in Tyrol have equal access to all therapeutic resources (surgery, radiotherapy and hormonal therapy) and that diagnosis and therapy are free of charge for everyone. [39] search for evidence of a change point, with a consequent reduction in power when adjusting for multiple testing. Secondly we expect to find the same trends in all age groups and have carried out a pooled analysis, adjusting for age effects, while Vutuc et al. [39] carried out a stratified analysis fitting the same model 8 times. Admittedly most of the power in both analyses comes from the 70-79 age group where most deaths are observed and the interaction tests we carried out to establish if there was any evidence that the trends in the two areas post 1993 were different in the age groups have low power. The analysis presented here and in Bartsch et al. [19] is based upon the estimation of effects and it can be concluded that there is evidence that the rates in both areas of Austria have decreased since 1993 and that there is evidence that the rate of decrease is faster in Tyrol. When estimating a change point there is sampling error in this estimation and an associated confidence interval and this is not reported by Vutuc et al. [39] . We have carried out a sensitivity analysis from 1991 to 1995 and at each year there was evidence of a change in slope (on our pooled analysis). Furthermore there was evidence that the reduction in mortality in Tyrol is greater than the reduction in the rest of Austria.
Data from the Tyrol have been presented here using the same approach as in the previous report [19] for maintaining longitudinal transparency of our study findings. These findings continue to be consistent with the notion that making PSA testing freely available, and its wide acceptance by men in the population, is associated with a reduction in prostate cancer mortality in a region where potentially curative prostate cancer treatment services are available free of charge to all patients.
Although it is not possible from the available data to separate the individual contributions of PSA testing and curative treatment to the favourable outcomes, the more rapid accelerated decline in mortality rates in Tyrol compared with the rest of Austria is unlikely to be artefactual. The delay between early detection and radical treatment beginning in 1988 (accelerating in 1993) and the decline in mortality in the targeted age range, which started in 1996, is comparable with that seen in other screening programmes with high compliance. It is likely that much of this decline in mortality rates is due to earlier detection and successful treatment of prostate cancer. However, an important corollary implication of the present study is that screening is only the first step in the optimal management of patients with prostate cancer.
Pending the results of the large randomized clinical trials, there is a great public health need to know more details of the potential risks and benefits of PSA testing. However, it is likely that, given the penetrance of PSA testing in communities of men, even null findings from these randomised trials will not deter future PSA testing rates [37] .
The study group described here is a welldefined population of Tyrol, where detailed knowledge of PSA testing rates and information on therapy offered to the population exist. Of course, the design of the present study cannot overcome the problems inherent in nonrandomized studies, but it can provide useful information on the potential benefits of early detection in a real-life setting.
